公开(公告)号：US20240327381A1

公开(公告)日：2024-10-03

申请号：US18435117

申请日：2024-02-07

申请人： Celgene Corporation ,  Bristol-Myers Squibb Company

发明人： Laura Akullian D'Agostino ,  Godwin Kumi ,  Haibo Liu

IPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/00 ,  C07D471/04

CPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/00 ,  C07D471/04

摘要： Provided herein are compounds and compositions thereof for degrading an engineered polypeptide in a cell. In some embodiments, the compounds and compositions are provided for treatment of cancer.

公开(公告)号：US20230322695A1

公开(公告)日：2023-10-12

申请号：US18161184

申请日：2023-01-30

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Haibo Liu ,  Laura Akullian D′Agostino ,  Shoshana L. Posy ,  Annapurna Pendri ,  Swanee E. Jacutin-Porte

IPC分类号： C07D285/06 ,  A61K45/06 ,  A61P35/00 ,  C07D417/12 ,  C07D417/10

CPC分类号： C07D285/06 ,  A61K45/06 ,  A61P35/00 ,  C07D417/10 ,  C07D417/12

摘要： Disclosed are compounds of Formula (I)





pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.

公开(公告)号：US20230095912A1

公开(公告)日：2023-03-30

申请号：US17817777

申请日：2022-08-05

申请人： Celgene Corporation

发明人： Christopher Walton Carroll ,  Laura Akullian D'Agostino ,  Haibo Liu ,  Veerabahu Shanmugasundaram ,  Brook Barajas

IPC分类号： C07K14/47 ,  C07K14/725

摘要： The present disclosure relates to engineered polypeptides comprising degradation domains, compounds, compositions, and methods for their preparation and use as for degrading engineered proteins in cells.